Frontlight ResearchEarly access
CompletedNo phase
Characterization and Modulation of Traumatic Memories in PTSD Patients Using TMS
Key facts
- Who runs it
- Tel Aviv University
- Where
- Israel1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 10 people enrolled
- Started
- 23 Feb 2022
- Ended
- 24 Oct 2024
- Type of study
- Interventional, 2 groupsOne group gets a sham (pretend) treatment, for comparison.
- Treatments tested
- Trans-Cranial Magnetic Stimulation
- Record updated
- 1 November 2024
Who can take part
- Age
- 20 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Adults aged 20-65 of both sexes, who meet the diagnosis of PTSD according to DSM-5 as tested by a structured clinical interview (Clinician-Administered PTSD Scale - CAPS-5). The clinical interview will be performed by clinical psychologists
- CAPS-5 (Clinician-Administered PTSD Scale) score higher than 33
- Subjects who experience intrusive symptoms (flashbacks, nightmares, or intrusive memories) at least 4 times a week
- Only subjects with a level of Hebrew that allows a full understanding of the consent form to participate in the experiment will be included in the experiment
- In addition, the accepted criteria for inclusion for an MRI examination for medical purposes will be applied, according to the established procedures at the MRI Institute at the Sourasky Tel Aviv Medical Center and at the Imaging Center at Tel Aviv University
Who cannot take part
- Use of the following drugs:; The list of drugs that constitute a criterion for exclusion in the study: imipramine, amitriptyline, doxepine, nortriptyline, maprotiline, chlorpromazine, clozapine, foscarnet, ganciclovir, ritonavir, amphetamines, cocaine, (MDMA, ecstasy), phencyclidine (PCP, angel's dust), ketamine, gamma- hydroxybutyrate (GHB), alcohol, theophylline
- Victims with traumatic head injuries or who have undergone head surgery
- Subjects who use drugs
- Subjects who have previously experienced repeated episodes of fainting with loss of consciousness and/or an event of fainting with loss of consciousness in the past year. (reaction and vegalit)
- Subjects who meet the diagnosis of Complex PTSD or personality disorder
- Subjects who suffer or have suffered in the past from a psychotic disorder, bipolar disorder, or a developmental neuropsychological disorder (autism, mental retardation)
- Use of psychiatric medications (except for the medications listed in section 4.a) will not be an expense criterion if the medication dosage is stable in the last three months and does not change during the study; In addition, exclusion criteria 4-13 will apply according to the exclusion rules in TMS laboratories in England and the USA:
- Subjects suffering from epilepsy or taking anti-epileptic drugs
- Having a metallic body (except fillings/amalgam bites/orthodontic fixations approved for MRI), electrodes or a pacemaker in their body
- Subjects suffering from migraines
- Pregnant women
- Subjects with hearing problems
- Subjects who drank alcohol 24 hours before the experiment
- In addition, the accepted exclusion criteria for an MRI examination for medical purposes will apply, according to the established procedures at the MRI Institute at the Sourasky Tel Aviv Medical Center and at the Imaging Center at Tel Aviv University
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Characterization and modulation of traumatic memories in PTSD patients using TMS.
The 2 groups in the trial
- Hippocampus StimulationTreatment being tested
Treatment: Trans-Cranial Magnetic Stimulation
- Sham StimulationSham treatment, for comparison
Treatment: Trans-Cranial Magnetic Stimulation
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Record updated
- 1 November 2024